AAV-mediated gene therapy for atherosclerosis (Q38236204)

31 August 2017

title

AAV-mediated gene therapy for atherosclerosis (English)

1 reference

31 August 2017

0 references

1 reference

2

Corinna Lebherz

1 reference

31 August 2017

Michael Lehrke

1

1 reference

31 August 2017

publication date

1 September 2014

1 reference

Current Atherosclerosis Reports

31 August 2017

published in

1 reference

31 August 2017

volume

16

1 reference

31 August 2017

issue

9

1 reference

31 August 2017

page(s)

434

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-014-0434-0

31 August 2017

exact match

0 references

cites work

Gene therapy clinical trials worldwide to 2012 - an update.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Adenoviral vectors for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Retroviral DNA integration: viral and cellular determinants of target-site selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Self-complementary AAV vectors; advances and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Humoral Immune Response to AAV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Developing immunologically inert adeno-associated virus (AAV) vectors for gene therapy: possibilities and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Complete prevention of atherosclerosis in apoE-deficient mice by hepatic human apoE gene transfer with adeno-associated virus serotypes 7 and 8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Human apolipoprotein E expression from mouse skeletal muscle by electrotransfer of nonviral DNA (plasmid) and pseudotyped recombinant adeno-associated virus (AAV2/7).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Gene transfer of apolipoprotein A-V improves the hypertriglyceridemic phenotype of apoa5 (-/-) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Persistent liver expression of murine apoA-l using vectors based on adeno-associated viral vectors serotypes 5 and 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

AAV gene therapy as a means to increase apolipoprotein (Apo) A-I and high-density lipoprotein-cholesterol levels: correction of murine ApoA-I deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Apolipoprotein B knockdown by AAV-delivered shRNA lowers plasma cholesterol in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery dis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Paradoxical effects on force generation after efficient β1-adrenoceptor knockdown in reconstituted heart tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Systemic delivery of shRNA by AAV9 provides highly efficient knockdown of ubiquitously expressed GFP in mouse heart, but not liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

AAV/hSTAT3-gene delivery lowers aortic inflammatory cell infiltration in LDLR KO mice on high cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Suppression of atherogenesis by delivery of TGFbeta1ACT using adeno-associated virus type 2 in LDLR knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Adeno-associated virus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor reduces atherosclerotic lesion formation in LDL receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Glucagon-like peptide-1 gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Double-strand adeno-associated virus-mediated exendin-4 expression in salivary glands is efficient in a diabetic rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

In vivo expression of HGF/NK1 and GLP-1 From dsAAV vectors enhances pancreatic ß-cell proliferation and improves pathology in the db/db mouse model of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe⁻/⁻ mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

AAV-mediated gene therapy for heart failure: enhancing contractility and calcium handling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Cardiovascular gene therapy for myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0434-0

RNAi and gene therapy: a mutual attraction

21 January 2018

1 reference

12 December 2020

Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies

1 reference

12 December 2020

The gene therapy journey for hemophilia: are we there yet?

1 reference

12 December 2020

Apolipoprotein A5 gene variants and the risk of coronary heart disease: a case‑control study and meta‑analysis

1 reference

12 December 2020

Dual AAV/IL-10 Plus STAT3 Anti-Inflammatory Gene Delivery Lowers Atherosclerosis in LDLR KO Mice, but without Increased Benefit

1 reference

12 December 2020

10.1007/S11883-014-0434-0

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1005650082

0 references

1 reference